Healthcare resource use associated with the diagnosis of transthyretin amyloidosis cardiomyopathy.

ABSTRACT:

Objectives

Our primary aim was to evaluate the healthcare resource use associated with the diagnosis of transthyretin amyloidosis cardiomyopathy. Second, we aim to assess the effect of the number of diagnostic tests and clinical contact points on the total time and costs between symptom onset and diagnosis defining a quantitative hypothetical optimized diagnostic pathway.

Setting

Clinical and cost data were collected from patients presenting between 2010 and 2018 in a tertiary referral institution in South London involving two participating hospitals.

Participants

Thirty-eight adult patients with a definite diagnosis of transthyretin amyloidosis cardiomyopathy were included, mostly male (n = 28, 74%) and of African-Caribbean descent (n = 23, 64%). We excluded patients

SUBMITTER: Asher C 

PROVIDER: S-EPMC8733838 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature